NewBiologix

NewBiologix is an AAV-centered biotechnology company. NewBiologix is developing a proprietary breakthrough DNA integration platform for advanced engineering of human and mammalian cell lines. Currently, it focuses on recombinant adeno-associated virus (rAAV) vectors, the preferred delivery vehicle for gene therapy. Specifically, the company’s technology will be applied to human (HEK-293) and mammalian (CHO) cell lines. These cell lines will be engineered to be easily adaptable to meet the requirements of viral vectors and various therapeutic indications, thereby helping partners address rare, chronic, and currently incurable diseases.